- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
North Chicago Today
By the People, for the People
Brookstone Capital Management Trims AbbVie Stake
Investment firm sells over 6,000 shares of pharmaceutical giant
Mar. 31, 2026 at 8:36am
Got story updates? Submit your updates here. ›
An extreme close-up of the inner workings of a pharmaceutical production facility highlights the industrial might behind major drug companies like AbbVie.North Chicago TodayBrookstone Capital Management, an investment management firm, reduced its stake in AbbVie Inc. (NYSE: ABBV) by 6.4% in the fourth quarter, according to a recent SEC filing. The firm sold 6,299 shares of the pharmaceutical company's stock, leaving it with a remaining position of 91,414 shares valued at $20.9 million.
Why it matters
AbbVie is a major player in the pharmaceutical industry, known for blockbuster drugs like Humira. Tracking institutional investor activity in the stock can provide insights into market sentiment and potential future performance.
The details
Brookstone Capital Management's reduced position in AbbVie comes as the stock has seen some volatility in recent months, trading between a 52-week low of $164.39 and a high of $244.81. The firm's sale of over 6,000 shares represents a small portion of its overall holding in the company.
- Brookstone Capital Management filed the SEC disclosure on March 31, 2026.
- The firm sold the shares during the fourth quarter of 2025.
The players
Brookstone Capital Management
An investment management firm that reduced its stake in pharmaceutical company AbbVie.
AbbVie Inc.
A global biopharmaceutical company that develops and commercializes therapies for complex and chronic medical conditions.
The takeaway
The reduction in Brookstone Capital Management's AbbVie position reflects the ongoing volatility in the stock, which has seen significant price swings over the past year. Investors will be closely watching to see if other institutional investors follow suit or if AbbVie can regain momentum.
